Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

Drug discovery has long been criticized for its slow, costly, and failure-prone nature. Traditional approaches, particularly ...

The FDA has placed the credibility of AI's 'context of use' in pharma development at the heart of its first guidance in this area.

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...

Reflecting on the future The integration of AI into drug submission and approval processes signifies a shift towards more efficient pharmaceutical development.

The analysis reveals a strong dominance of AI applications in oncology, comprising 72.8% of all included studies. This skew reflects the data-rich nature of cancer research, commercial incentives, and ...

The global AI in drug discovery market size was US$ 910.7 million in 2021. The global AI in drug discovery market size is forecast to reach US$ 9,072.2 million by 2030, growing at a compound annual ...

The Global Generative Artificial Intelligence (GenAI) in Healthcare Market is expected to witness a growth rate of 36-38% in ...

Drug Development Drug services firms begin embracing AI Pharmaceutical manufacturers are using AI tools and robots to speed up drug development and handle mundane lab tasks by Aayushi Pratap May ...

DHA R&D-MRDC researchers are applying the latest regulatory guidance related to AI to better carry out their mission to develop life-saving medicines.

$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx in ...

Intrepid Labs was spun out of the University of Toronto to pioneer the use of artificial intelligence and robotics to redefine drug formulation and accelerate therapeutic development.